Cullinan Therapeutics shares updated clinical data from Phase 1 study of CLN-049

Cullinan Therapeutics (CGEM) shared updated clinical data from its Phase 1 study of CLN-049, a novel, investigational FLT3xCD3 bispecific T cell engager, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. These data will be presented at the 67th American Society of Hematology Annual Meeting and Exposition, being held December 6-9, as an oral presentation on Monday, December 8, at 10:45 a.m. ET. “These promising clinical data, including multiple complete responses and encouraging initial data for response durability, demonstrate the potential for CLN-049 to expand treatment options for a broad population of people with AML, including patients with TP53-mutated AML who currently face a particularly poor prognosis,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “Coupled with recent Fast Track designation from the FDA, which underscores the promise of CLN-049 to help patients with AML, Cullinan is committed to rapidly advancing this potential new treatment option for a devastating disease.”